Activ-Vial will be produced at the company’s facility in Guangzhou, providing a best-in-class offering for the country’s growing diagnostics market, particularly for patients with diabetes conditions where blood glucose monitoring is a critical component of care.
By locally manufacturing Activ-Vial, Aptar CSP Technologies will bring production closer to the local customer, mitigating supply chain disruptions, and more importantly, providing an optimal solution to the local diabetes patient. The move is a key component of the company’s strategic effort to significantly expand its market presence in China.
“This latest investment in local production expansion reflects our continued commitment to serving the China market,” said Badre Hammond, VP Global Commercial Operations, Aptar CSP Technologies. “This initiative not only represents an investment in the markets and communities we serve, but allows us to leverage local supply chains, improving our cost structure and sustainability of operations.”
